These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 6177592)

  • 1. [Use of chromogenic substrates in the clarification of disorders in the early stages of blood coagulation].
    Vogel G; Stürzebecher J; Klessen C; Lauten G
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(1):115-20. PubMed ID: 6177592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Determination of factor XII and plasma prekallikrein with chromozym PK].
    Stürzebecher J; Klessen C; Markwardt F
    Z Med Lab Diagn; 1982 Oct; 23(5):306-11. PubMed ID: 6924817
    [No Abstract]   [Full Text] [Related]  

  • 3. [Studies on plasma prekallikrein assay method with chromogenic substrates (S-2302)].
    Fukuda C; Iijima K; Nakamura K
    Rinsho Byori; 1983 Feb; 31(2):219-22. PubMed ID: 6190027
    [No Abstract]   [Full Text] [Related]  

  • 4. Chromogenic peptide substrate assays for determining components of the plasma kallikrein system.
    Gallimore MJ
    Scand J Clin Lab Invest Suppl; 1985; 178():127-32. PubMed ID: 3867113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assay of Fletcher factor (plasma prekallikrein) using an artificial clotting reagent and a modified chromogenic assay.
    Soulier JP; Gozin D
    Thromb Haemost; 1979 Aug; 42(2):538-47. PubMed ID: 505362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma prekallikrein: quantitative determination by direct activation with Hageman factor fragment (beta-XIIa).
    Alving BM; Tankersley DL; Mason BL
    J Lab Clin Med; 1983 Feb; 101(2):226-41. PubMed ID: 6549773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enzymes of the contact phase of blood coagulation: kinetics with various chromogenic substrates and a two-substrate assay for the joint estimation of plasma prekallikrein and factor XI.
    Retzios AD; Rosenfeld R; Schiffman S
    J Lab Clin Med; 1988 Nov; 112(5):560-6. PubMed ID: 3263454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kallikrein and prekallikrein levels in a large number of congenital clotting deficiencies and abnormalities.
    Patrassi GM; Martinelli S; Vianello C; Girolami A
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(4):644-54. PubMed ID: 6184289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hageman factor deficiency presentation and implications for management.
    Harper K; Friedland ML
    Conn Med; 1992 Sep; 56(9):469-71. PubMed ID: 1424610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fletcher factor deficiency. A diminished rate of Hageman factor activation caused by absence of prekallikrein with abnormalities of coagulation, fibrinolysis, chemotactic activity, and kinin generation.
    Weiss AS; Gallin JI; Kaplan AP
    J Clin Invest; 1974 Feb; 53(2):622-33. PubMed ID: 11344577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the clotting defect in a factor XII-deficient kindred.
    Chistolini A; Mazzucconi MG; Motta M; Solinas S; Tirindelli MC; Mariani G
    Ric Clin Lab; 1985; 15(3):241-5. PubMed ID: 3853270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Report 2 cases of congenital factor XII deficiency: a rare coagulation disorder.
    Kanjanapongkul S
    J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S231-2. PubMed ID: 22043782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chromogenic peptide substrate assays in patients with multiple trauma.
    Kierulf P; Aasen AO; Aune S; Godal HC; Ruud TE; Vaage J
    Acta Chir Scand Suppl; 1982; 509():69-72. PubMed ID: 6962622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factor-XII congenital deficiency. A new family study.
    Lucia JF; Ercoreca L; Torres M; Giralt M; Raichs A
    Thromb Haemost; 1979 Oct; 42(3):1009-17. PubMed ID: 505391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factor XII Osaka: abnormal factor XII with partially defective prekallikrein cleavage activity.
    Iijima K; Arakawa Y; Sugahara Y; Matsushita M; Moriguchi Y; Shimohiro H; Nakagawa M
    Thromb Haemost; 2011 Mar; 105(3):473-8. PubMed ID: 21264442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Factor XII (Hageman factor) deficiency: a risk factor for development of thromboembolism. Incidence of factor XII deficiency in patients after recurrent venous or arterial thromboembolism and myocardial infarction].
    Halbmayer WM; Mannhalter C; Feichtinger C; Rubi K; Fischer M
    Wien Med Wochenschr; 1993; 143(2):43-50. PubMed ID: 8488686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical significance of factor XII analysis in blood coagulation tests].
    Saito H
    Nihon Rinsho; 1989 Dec; 48 Suppl():843-5. PubMed ID: 2622016
    [No Abstract]   [Full Text] [Related]  

  • 18. [Factor XII (Hageman factor)].
    Saito H
    Nihon Rinsho; 2004 Dec; 62 Suppl 12():657-9. PubMed ID: 15658416
    [No Abstract]   [Full Text] [Related]  

  • 19. A novel chromogenic peptide for prekallikrein/kallikrein determination.
    Huang WY; Wan X; Zhang S
    Clin Lab; 2009; 55(3-4):106-13. PubMed ID: 19462932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hageman factor deficiency (factor XII)--hemorrhage or thrombosis?].
    Schott G; Lutze G
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1985; 112(3):436-41. PubMed ID: 2414173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.